Analyst Ratings For NASDAQ:LGND – Ligand Pharmaceuticals (NASDAQ:LGND)
Today, HC Wainwright reiterated its Buy rating on NASDAQ:LGND – Ligand Pharmaceuticals (NASDAQ:LGND) with a price target of $182.00.
Some recent analyst ratings include
- 5/9/2018-HC Wainwright Reiterated Rating of Buy.
- 3/7/2018-Craig Hallum Reiterated Rating of Buy.
- 11/20/2017-Deutsche Bank was Downgraded by analysts at Deutsche Bank from a “Hold ➝ Sell” rating to a “” rating. They now have a $105.00 price target on the stock.
- 8/9/2017-Stephens Reiterated Rating of Overweight.
- On 4/2/2018 John W Kozarich, Director, sold 2,500 with an average share price of $160.43 per share and the total transaction amounting to $401,075.00.
- On 3/12/2018 Stephen L Sabba, Director, sold 622 with an average share price of $180.73 per share and the total transaction amounting to $112,414.06.
- On 3/9/2018 Jason Aryeh, Director, sold 7,500 with an average share price of $175.73 per share and the total transaction amounting to $1,317,975.00.
- On 3/5/2018 John L Lamattina, Director, sold 3,335 with an average share price of $160.90 per share and the total transaction amounting to $536,601.50.
- On 2/27/2018 Todd C Davis, Director, sold 17,170 with an average share price of $152.37 per share and the total transaction amounting to $2,616,192.90.
- On 2/23/2018 Jason Aryeh, Director, sold 3,417 with an average share price of $155.00 per share and the total transaction amounting to $529,635.00.
- On 2/23/2018 Matthew W Foehr, COO, sold 5,444 with an average share price of $152.98 per share and the total transaction amounting to $832,823.12.
Recent Trading Activity for NASDAQ:LGND – Ligand Pharmaceuticals (NASDAQ:LGND)
Shares of NASDAQ:LGND – Ligand Pharmaceuticals closed the previous trading session at 167.41 up +10.13 6.44% with 168.88999938964844 shares trading hands.